{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:32:29Z","timestamp":1783744349035,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174077"],"award-info":[{"award-number":["82174077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYGD20001"],"award-info":[{"award-number":["ZYGD20001"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFS0230"],"award-info":[{"award-number":["2021YFS0230"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023NSFSC1772"],"award-info":[{"award-number":["2023NSFSC1772"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115234","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T21:26:27Z","timestamp":1677792387000},"page":"115234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["From lead to clinic: A review of the structural design of P2X7R antagonists"],"prefix":"10.1016","volume":"251","author":[{"given":"Ruijia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115234_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2015.12.001","article-title":"Medicinal chemistry of adenosine, P2Y and P2X receptors","volume":"104","author":"Jacobson","year":"2016","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/mol.112.083758","article-title":"P2X receptors as drug targets","volume":"83","author":"North","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115234_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2X7 receptor: a main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115234_bib4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","article-title":"The elusive P2X7 macropore","volume":"28","author":"Di Virgilio","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115234_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fphar.2018.00052","article-title":"The P2X7 receptor in inflammatory diseases: angel or demon?","volume":"9","author":"Savio","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5262","key":"10.1016\/j.ejmech.2023.115234_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.272.5262.735","article-title":"The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)","volume":"272","author":"Surprenant","year":"1996","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.ejmech.2023.115234_bib7","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1074\/jbc.275.14.10190","article-title":"A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X(2) ATP-gated channels","volume":"275","author":"Boue-Grabot","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.4049\/jimmunol.167.4.1871","article-title":"Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide","volume":"167","author":"Denlinger","year":"2001","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115234_bib9","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1074\/jbc.272.9.5482","article-title":"The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA","volume":"272","author":"Rassendren","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115234_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bj.2019.05.007","article-title":"Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: myth or reality?","volume":"42","author":"Benzaquen","year":"2019","journal-title":"Biomed. J."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/187221511794839219","article-title":"Significance of P2X7 receptor variants to human health and disease","volume":"5","author":"Sluyter","year":"2011","journal-title":"Recent Pat. DNA Gene Sequences"},{"issue":"10","key":"10.1016\/j.ejmech.2023.115234_bib13","doi-asserted-by":"crossref","first-page":"13533","DOI":"10.1007\/s13277-016-5141-8","article-title":"P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma","volume":"37","author":"Pan","year":"2016","journal-title":"Tumor Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib14","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1074\/jbc.M507816200","article-title":"A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages","volume":"281","author":"Shemon","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115234_bib15","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1096\/fj.09-150862","article-title":"Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion","volume":"24","author":"Stokes","year":"2010","journal-title":"Faseb. J."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115234_bib16","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M010353200","article-title":"A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor","volume":"276","author":"Gu","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.ejmech.2023.115234_bib17","doi-asserted-by":"crossref","first-page":"31287","DOI":"10.1074\/jbc.M313902200","article-title":"An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor","volume":"279","author":"Gu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.175.1.82","article-title":"A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes","volume":"175","author":"Cabrini","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11302-009-9168-9","article-title":"Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function","volume":"6","author":"Sun","year":"2010","journal-title":"Purinergic Signal."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115234_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jpsychires.2009.10.005","article-title":"Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions","volume":"44","author":"Roger","year":"2010","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib21","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/0008-5472.CAN-11-1947","article-title":"Expression of P2X7 receptor increases in vivo tumor growth","volume":"72","author":"Adinolfi","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115234_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11302-009-9145-3","article-title":"P2X7: a growth-promoting receptor\u2014implications for cancer","volume":"5","author":"Di Virgilio","year":"2009","journal-title":"Purinergic Signal."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115234_bib23","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41388-019-0684-y","article-title":"The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment","volume":"38","author":"De Marchi","year":"2019","journal-title":"Oncogene"},{"issue":"41","key":"10.1016\/j.ejmech.2023.115234_bib24","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/onc.2014.444","article-title":"The P2X7 receptor is a key modulator of the PI3K\/GSK3\u03b2\/VEGF signaling network: evidence in experimental neuroblastoma","volume":"34","author":"Amoroso","year":"2015","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.ejmech.2023.115234_bib25","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1111\/jcmm.15708","article-title":"P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-\u03baB signalling pathway in colorectal cancer cells","volume":"24","author":"Yang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115234_bib26","doi-asserted-by":"crossref","unstructured":"Z. Wang, S. Zhu, S. Tan, Y. Zeng, H. Zeng, The P2 purinoceptors in prostate cancer, Purinergic Signal.., doi:10.1007\/s11302-022-09874-2.","DOI":"10.1007\/s11302-022-09874-2"},{"issue":"10","key":"10.1016\/j.ejmech.2023.115234_bib27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/1055-9965.EPI-06-0407","article-title":"The P2X7 receptor: a novel biomarker of uterine epithelial cancers","volume":"15","author":"Li","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ejmech.2023.115234_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.694831","article-title":"The P2X7 receptor in tumor immunity","volume":"9","author":"Grassi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115234_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2020.01.014","article-title":"Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP","volume":"52","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115234_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainresbull.2022.07.006","article-title":"P2X7 receptor in inflammation and pain","volume":"187","author":"Hu","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2023.115234_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114385","article-title":"P2X7 receptor and the NLRP3 inflammasome: partners in crime","volume":"187","author":"Pelegrin","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"7575","key":"10.1016\/j.ejmech.2023.115234_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115234_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41418-019-0366-x","article-title":"Magnesium protects against sepsis by blocking gasdermin D N-terminal-induced pyroptosis","volume":"27","author":"Wang","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2023.115234_bib34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/JIR.S351660","article-title":"ATP-activated P2X7R promote the attack of acute gouty arthritis in rats through activating NLRP3 inflammasome and inflammatory cytokine production","volume":"15","author":"Dai","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejmech.2023.115234_bib35","article-title":"P2X7 receptor induces pyroptotic inflammation and cartilage degradation in osteoarthritis via NF-\u03baB\/NLRP3 crosstalk","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2023.115234_bib36","article-title":"P2X7 receptor-mediated inflammation in cardiovascular disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib37","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1038\/s41598-017-05137-y","article-title":"P2X7 receptor antagonism modulates IL-1\u03b2 and MMP9 in human atherosclerotic vessels","volume":"7","author":"Lombardi","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib38","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.3390\/ijms22126545","article-title":"Purine nucleotides metabolism and signaling in huntington's disease: search for a target for novel therapies","volume":"22","author":"Tomczyk","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41380-018-0108-3","article-title":"New role of P2X7 receptor in an Alzheimer's disease mouse model","volume":"24","author":"Martin","year":"2019","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3858\/emm.2011.43.1.001","article-title":"Microglial P2X7 receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe\/PS1dE9 mouse model of Alzheimer's disease","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115234_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314753","article-title":"Pathogenesis of \u03b1-Synuclein in Parkinson's disease: from a neuron-glia crosstalk perspective","volume":"23","author":"Yi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115234_bib42","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.3390\/ijms21113959","article-title":"P2X7 receptor is involved in mitochondrial dysfunction induced by extracellular alpha synuclein in neuroblastoma SH-SY5Y cells","volume":"21","author":"Wilkaniec","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115234_bib43","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1111\/ene.14918","article-title":"P2X7 receptor\/NLRP3 inflammasome complex and \u03b1-synuclein in peripheral blood mononuclear cells: a prospective study in neo-diagnosed, treatment-na\u00efve Parkinson's disease","volume":"28","author":"Solini","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41531-022-00394-9","article-title":"Cathepsin L-containing exosomes from \u03b1-synuclein-activated microglia induce neurotoxicity through the P2X7 receptor","volume":"8","author":"Jiang","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"23","key":"10.1016\/j.ejmech.2023.115234_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312936","article-title":"The tyrosine phosphatase hPTPR\u03b2 controls the early signals and dopaminergic cells viability via the P2X7 receptor","volume":"22","author":"Bernal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115234_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fnmol.2020.00111","article-title":"ATP signaling controlling dyskinesia through P2X7 receptors","volume":"13","author":"Fonteles","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115234_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuropharm.2016.01.018","article-title":"P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy","volume":"105","author":"Amhaoul","year":"2016","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib48","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3390\/ijms23042380","article-title":"Beyond seizure control: treating comorbidities in epilepsy via targeting of the P2X7 receptor","volume":"23","author":"Gil","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115234_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114942","article-title":"The P2X7 receptor as a new pharmacological target for retinal diseases","volume":"198","author":"Platania","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115234_bib50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bcp.2017.05.001","article-title":"P2X7 receptor antagonism: implications in diabetic retinopathy","volume":"138","author":"Platania","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib51","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00125-022-05775-6","article-title":"Disruption of retinal inflammation and the development of diabetic retinopathy in mice by a CD40-derived peptide or mutation of CD40 in Muller cells","volume":"65","author":"Portillo","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2023.115234_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2019.07.010","article-title":"Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor","volume":"168","author":"Platania","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41419-022-04786-w","article-title":"Targeted P2X7\/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy","volume":"13","author":"Kong","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115234_bib54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.exer.2014.08.009","article-title":"Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, M\u00fcller cells, lens, trabecular meshwork, cornea and lacrimal gland","volume":"127","author":"Sanderson","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2023.115234_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainresbull.2019.05.006","article-title":"Potential role of P2X7 receptor in neurodegenerative processes in a murine model of glaucoma","volume":"150","author":"Perez de Lara","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2023.115234_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114199","article-title":"P2X7 receptor antagonism preserves retinal ganglion cells in glaucomatous mice","volume":"180","author":"Romano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115234_bib57","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejmech.2018.03.023","article-title":"Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells","volume":"151","author":"Kwak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.tet.2017.10.075","article-title":"The role of polycyclic frameworks in modulating P2X7 receptor function","volume":"74","author":"Callis","year":"2018","journal-title":"Tetrahedron"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bmcl.2017.01.039","article-title":"Escape from adamantane: scaffold optimization of novel P2X7 antagonists featuring complex polycycles","volume":"27","author":"Barniol-Xicota","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115234_bib60","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.bmcl.2019.04.033","article-title":"Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists","volume":"29","author":"Xiao","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115234_bib61","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acschemneuro.7b00272","article-title":"Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 receptor antagonist","volume":"8","author":"Wilkinson","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115234_bib62","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/cmdc.202000303","article-title":"Design, synthesis, and in vitro evaluation of P2X7 antagonists","volume":"15","author":"Pournara","year":"2020","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/ni.2474","article-title":"Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome\u2013dependent processing of IL-1\u03b2","volume":"14","author":"Mishra","year":"2013","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115234_bib64","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1021\/acs.jmedchem.9b00584","article-title":"Pyroglutamide-based P2X7 receptor antagonists targeting inflammatory bowel disease","volume":"63","author":"Homerin","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115234_bib65","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1021\/acs.jmedchem.0c02249","article-title":"Synthesis and characterization of the novel rodent-active and CNS-penetrant P2X7 receptor antagonist Lu AF27139","volume":"64","author":"Hopper","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128361","article-title":"Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity","volume":"51","author":"Zhao","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115234_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bmcl.2015.12.052","article-title":"Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists","volume":"26","author":"Ameriks","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115234_bib68","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1021\/acs.jmedchem.6b00989","article-title":"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor","volume":"59","author":"Swanson","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib69","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/acschemneuro.5b00304","article-title":"Substituted 5,6-(dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 antagonists","volume":"7","author":"Ziff","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115234_bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/acsmedchemlett.5b00089","article-title":"Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists","volume":"6","author":"Savall","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115234_bib71","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/acs.jmedchem.7b00408","article-title":"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate","volume":"60","author":"Letavic","year":"2017","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib72","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/0269881118800067","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants","volume":"32","author":"Timmers","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2023.115234_bib73","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejmech.2017.08.034","article-title":"1-Aryl-1H- and 2-aryl-2H-1,2,3-triazole derivatives blockade P2X7 receptor in vitro and inflammatory response in vivo","volume":"139","author":"Gonzaga","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115234_bib74","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bmc.2018.11.036","article-title":"8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 receptor-induced dye uptake into murine macrophages","volume":"27","author":"Pacheco","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10863-022-09947-2","article-title":"Synthesis, biological evaluation and molecular modeling studies of novel 1,2,3-triazole-linked menadione-furan derivatives as P2X7 inhibitors","volume":"54","author":"dos Santos","year":"2022","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.ejmech.2023.115234_bib76","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ejmech.2017.10.033","article-title":"1,4-Naphthoquinones potently inhibiting P2X7 receptor activity","volume":"143","author":"Faria","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib77","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1021\/acs.jmedchem.0c02145","article-title":"Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation","volume":"64","author":"Calzaferri","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib78","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2017.02.060","article-title":"Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists","volume":"130","author":"O'Brien-Brown","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113838","article-title":"Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists","volume":"226","author":"Patberg","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114491","article-title":"Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors","volume":"238","author":"Mahmood","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115234_bib81","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1021\/jm700949w","article-title":"Discovery of potent and selective adamantane-based small-molecule P2X7 receptor antagonists\/interleukin-1\u03b2 inhibitors","volume":"50","author":"Furber","year":"2007","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115234_bib82","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115234_bib83","first-page":"2247","article-title":"Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohn's disease: a randomized placebo-controlled, double-blind, phase IIa study","volume":"21","author":"Eser","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","article-title":"Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects","volume":"75","author":"Ali","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib85","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2215-0366(20)30255-8","article-title":"Neuroinflammation in psychiatric disorders: PET imaging and promising new targets","volume":"7","author":"Meyer","year":"2020","journal-title":"Lancet Psychiatr."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115234_bib86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2014.08.002","article-title":"P2X7 receptor: an emerging target in central nervous system diseases","volume":"35","author":"Sperl\u00e1gh","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115234_bib87","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbi.2017.01.005","article-title":"Critical role of P2X7 receptors in the neuroinflammation and cognitive dysfunction after surgery","volume":"61","author":"Zheng","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115234_bib88","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881120914206","article-title":"Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial","volume":"34","author":"Recourt","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115234_bib89","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41386-018-0141-6","article-title":"Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia","volume":"43","author":"Bhattacharya","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115234_bib90","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/0929867329666220629141418","article-title":"Recent advances in the development of antidepressants targeting the purinergic P2X7 receptor","volume":"30","author":"Lee","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115234_bib91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acs.jmedchem.7b01279","article-title":"A dipolar cycloaddition reaction to access 6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines enables the discovery synthesis and preclinical profiling of a P2X7 antagonist clinical candidate","volume":"61","author":"Chrovian","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib92","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0168-8278(18)30341-6","article-title":"Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"68","author":"Dabbagh","year":"2018","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115234_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234038","article-title":"Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis","volume":"15","author":"Baeza-Raja","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115234_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108228","article-title":"Development and clinical translation of P2X7 receptor antagonists: a potential therapeutic target in coronary artery disease?","volume":"237","author":"Genetzakis","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115234_bib95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-444-63380-4.00002-0","article-title":"P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders","volume":"53","author":"Chrovian","year":"2014","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115234_bib96","series-title":"Eli Lilly and Company","article-title":"Lilly and Asahi Kasei Pharma announce license agreement for chronic pain drug candidate","author":"Lilly","year":"2021"},{"issue":"17","key":"10.1016\/j.ejmech.2023.115234_bib97","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1016\/j.bmcl.2010.07.033","article-title":"Discovery and structure\u2013activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor","volume":"20","author":"Abdi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115234_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116996","article-title":"Hetero-aryl bromide precursor fluorine-18 radiosynthesis and preclinical evaluation of a novel positron emission tomography (PET) tracer [(18)F]GSK1482160","volume":"73","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115234_bib99","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MNM.0000000000000660","article-title":"Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response","volume":"38","author":"Han","year":"2017","journal-title":"Nucl. Med. Commun."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115234_bib100","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.bmcl.2011.04.077","article-title":"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535, Bioorg","volume":"21","author":"Duplantier","year":"2011","journal-title":"Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115234_bib101","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115234_bib102","first-page":"878","article-title":"Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism","volume":"32","author":"McInnes","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115234_bib103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.2014.873785","article-title":"Discontinued drug projects in the respiratory therapeutic area during 2012","volume":"23","author":"Snell","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115234_bib104","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","article-title":"Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization","volume":"179","author":"McCarthy","year":"2019","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:47:53Z","timestamp":1759330073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":104,"alternative-id":["S0223523423002003"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115234","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From lead to clinic: A review of the structural design of P2X7R antagonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115234"}}